The Department of Labor issued new guidance to delay enforcement of a recent rule related to drug manufacturer coupons. The ruling is due to a conflict it had with an earlier ruling, but now there is more confusion and another ruling is expected later this year.  Under the new interpretation, insurers and plans DO NOT have to count the value of a drug manufacturer coupon toward the annual cost sharing limit when a generic equivalent is available.  This may imply, however, that they DO have to count it when a generic is unavailable.  Stay tuned.